The medications work. The question is whether people can take them.
“The medication supports recovery. The logistics undermine it.”
In 2022, an estimated 6.1 million Americans aged 12 or older were living with an opioid use disorder. That number isn’t just a data point from a federal survey. It represents mothers, sons, coworkers, neighbors, and friends whose lives have been reshaped by addiction.
For many of them, an evidence-based treatment exists: Medications for Opioid Use Disorder — MOUD.
But here’s what the clinical literature often glosses over: having access to the right medication is only half the equation. What happens after the prescription — when someone is back in their community, managing the chaos of rebuilding a life, navigating a parole schedule, or living miles from the nearest treatment facility — that’s where recovery is won or lost.
The adherence gap is real. And it’s costing lives.
What MOUD Is — and Why It Works
For decades, opioid use disorder was framed as a moral failing rather than a chronic medical condition. That framing shaped treatment approaches built around detoxification, willpower, and abstinence alone — strategies that repeatedly failed to produce durable outcomes.
So, what do we do?
The FDA has approved three medications for the treatment of OUD:
Buprenorphine
A partial opioid agonist that reduces cravings and withdrawal symptoms without producing euphoria. It can be prescribed by certified healthcare providers and taken in multiple forms, including sublingual tablets, films, and extended-release injections.
Methadone
A full opioid agonist that eliminates withdrawal symptoms and relieves cravings. It has decades of evidence behind it but can only be dispensed through specialized Opioid Treatment Programs (OTPs).
Naltrexone
An opioid antagonist that blocks opioid receptors entirely, preventing any rewarding effects from opioid use. It’s used after detoxification to support sustained recovery.
These medications aren’t “replacing one drug with another.” They’re treating a chronic medical condition with evidence-based tools — the same way we treat hypertension, diabetes, or asthma. MOUD has been shown to reduce overdose deaths, decrease illicit opioid use, increase treatment retention, improve employment outcomes, and even improve birth outcomes for pregnant individuals with OUD.
According to Optum Behavioral Health, MOUD is the single most effective intervention to treat OUD — more effectively than detoxification, inpatient treatment, or intensive outpatient treatment alone. When paired with counseling and behavioral therapies, it provides the whole-patient approach that recovery demands.
In 2023, the DEA eliminated the X-waiver requirement for providers. This meant that those licensed providers could prescribe buprenorphine. The FDA has actively campaigned to encourage primary care providers to screen for OUD and manage it collaboratively with patients. The barriers to prescribing are falling.
But prescribing isn’t the finish line. It’s the starting gate.
The Adherence Gap: Where Treatment Meets Real Life
Here’s an uncomfortable truth that anyone who has worked in recovery knows firsthand: a prescription that doesn’t get taken consistently is a prescription that doesn’t work. This is arguably the primary reason why patients drop out of treatment.
The CDC conducted an 18-month observational study of nearly 2,000 adults with OUD across 62 outpatient treatment facilities in 15 cities. At the start of the study, engagement was universal — 100% participation at baseline. Nearly half the people who started treatment were no longer engaged at 18 months. retention had dropped to 53%.
Nearly half the people who started treatment weren’t there at the end. That drop-off represents one of the most persistent challenges in OUD treatment: retention.
Why? The reasons are as varied as the people themselves — but they tend to cluster around a set of familiar barriers:
Geography
Methadone can only be dispensed at OTPs, and many communities — particularly rural ones — simply don’t have one nearby. The National Harm Reduction Coalition has documented a cruel irony: the communities with the highest rates of opioid-related deaths often have the lowest access to MOUD. For someone in rural Appalachia or a small town in the Southwest, “treatment on demand” is a concept, not a reality.
Logistics
Daily clinic visits are the traditional model for methadone — and sometimes for early-stage buprenorphine treatment. For someone juggling a job, childcare, a court schedule, or the basic demands of putting a life back together, those daily trips can become the thing that breaks their momentum.
Stigma
Walking into a treatment facility every day is visible. It marks you. For people trying to reintegrate into their communities — especially those returning from incarceration — that visibility can feel like wearing a scarlet letter. Stigma doesn’t just hurt feelings. It drives people away from the treatment that could save their lives.
The post-detox danger zone
Traditional detox-to-abstinence treatment doesn’t adequately address cravings, which are a primary driver of relapse. Worse, the detox process lowers tolerance — meaning that if someone does relapse, they’re at significantly higher risk of fatal overdose than they were before treatment. This is the cruelest gap in the system: a model that can make people more vulnerable, not less.
MOUD works exceptionally well when patients can take it consistently. The challenge is that the treatment system often requires patients to adapt to the medication model, rather than adapting the model to patient realities.
Poor adherence is not only a clinical failure — it is a cost multiplier across emergency care, inpatient utilization, and justice system involvement.
The Populations Being Left Behind
Some groups feel this adherence gap more than others.
Justice-involved individuals
Someone leaving jail or prison with an OUD diagnosis may receive a prescription or a referral — but the transition back to community is where continuity of care falls apart. The first days and weeks after release are the highest-risk period for overdose. Courts and supervision programs that participate in medication management need tools that work in the real world, not just in the controlled environment of a facility.
People in sober living and community-based recovery
They’ve often moved past the acute phase of treatment but still need consistent medication management. Without it, the risk of relapsing doesn’t disappear — it waits.
Consider a patient stabilized on buprenorphine, working full time, living in sober housing, and required to travel daily for observed dosing. The medication supports recovery. The logistics undermine it.
Rural and underserved communities
Providers are scarce. OTPs may be hours away. Telehealth can’t dispense a pill or confirm it was taken.
The phrase “treatment on demand” appears frequently in policy conversations. It’s an important goal. But treatment on demand without adherence on demand is an incomplete answer.
Technology as a Bridge: Meeting People Where They Are
The harm reduction movement has always been built on a simple principle: meet people where they are.
While perspectives on harm reduction vary, the objective is consistent: reduce barriers, expand options, and create realistic pathways for individuals seeking to improve their health.
Smart medication dispensing technology is the next step in that continuum.
The iPill™ Dispenser, currently in development with pilot programs launching in 2026, represents exactly this kind of thinking. It’s a secure, connected dispensing system designed to support medication adherence outside the four walls of a clinic.
What makes this approach meaningful isn’t the technology itself — it’s what technology enables:
> Consistency without clinic visits
> Visibility for providers
> Accountability for justice systems
> Dignity for the individual
This isn’t about replacing the provider-patient relationship. It’s about extending its reach.
A Call to Action: What Providers, Programs, and Systems Can Do Now
The evidence for MOUD is overwhelming. The policy landscape is shifting in the right direction. The X-waiver is gone. More providers can prescribe. More payers are covering treatment. But the adherence gap remains.
> Mental health and medical providers
> Treatment programs
> Justice system programs
> Payers and policymakers
The Human Variable
Behind every statistic in this article is a person. Someone’s child. Someone’s parent. Someone’s son — including my own.
The people injured by addiction deserve a system that meets them where they are.
We have the science. We have the medications. What we need now is the infrastructure to make adherence possible in the real world.
Resources:
1. FDA — Information about Medications for Opioid Use Disorder (MOUD). [fda.gov]
2. National Harm Reduction Coalition — Medication for Opioid Use Disorder Overview. [harmreduction.org]
3. PCSS — Medications for Opioid Use Disorder [pcssnow.org]
4. CDC — Medications for Opioid Use Disorder (MOUD) Study. [cdc.gov]
5. SAMHSA — Medications for Substance Use Disorders. [samhsa.gov]
6. Optum/ProviderExpress — Medications for Alcohol and Opioid Use Disorder. [providerexpress.com]
7. Washington State Health Care Authority — Medications for Opioid Use Disorder. [hca.wa.gov]
8. MACPAC — Medications for Opioid Use Disorder and Related Policies (October 2024). [macpac.gov]
